Global Stem Cell Cartilage Regeneration Market, by Stem Cell Type (Hematopoietic Stem Cells (HSCs), Pluripotent Stem Cells (iPSC/ESCs), Mesenchymal Stem Cells (MSCs)), by Treatment (Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation, Stem Cell Injections), By End User (Hospitals, Ambulatory Surgical Centers) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 403.5 Million in 2023 and is expected to exhibit a CAGR of 9.2% during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing funding by the key market players is expected to drive the global stem cell cartilage regeneration market over the forecast period. For instance, in February 2019, Mogry Ltd, a company aiming to transform the future development of cell therapies, announced a second close on its seed funding, bringing the total raised to US$ 3.7 million, he Company will use the funding to market novel IP and cell types generated using its proprietary direct cellular conversion platform, which will power the development and manufacture of lifesaving cell therapies across all therapeutic areas. The company is positioned to directly address growing markets that are unserved by approved cell therapies, such as cardiac repair and cartilage regeneration.
Global Stem Cell Cartilage Regeneration Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2019 as "coronavirus disease 2019" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.
During the COVID-19 pandemic most of the patients are being denied the elective surgaries as the lack of avalaibilities such as hospital beds and staff members toward providing care to patients which were undergoing the surgaries.
Global Stem Cell Cartilage Regeneration Market: Key Developments
Increasing number of successful surgeries with approved procedures is expected to drive the global stem cell cartilage regeneration market over the forecast period. For instance, in May 2019, data was published by Springer Nature Limited, according to that, Cartilage injuries are extremely common, and lesions are often present in asymptomatic patients. For instance, Curl et al.2 reported that 63%. knee arthroscopies for any indication identified chondral lesions, 32% of which had exposed bone, categorizing them as grade IV on the Outerbridge scale.
Browse 32 Market Data Tables and 24 Figures spread through 154 Pages and in-depth TOC on “Global Stem Cell Cartilage Regeneration Market, by Stem Cell Type (Hematopoietic Stem Cells (HSCs), Pluripotent Stem Cells (iPSC/ESCs), Mesenchymal Stem Cells (MSCs)), by Treatment (Microfracture, Osteochondral Transplant, Autologous Chondrocyte Implantation, Stem Cell Injections), By End User (Hospitals, Ambulatory Surgical Centers) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/stem-cell-cartilage-regeneration-market-2448
Key Takeaways of the Global Stem Cell Cartilage Regeneration Market:
- The global stem cell cartilage regeneration market is expected to exhibit a CAGR of 9.2% during the forecast period. For instance, in July 2022, according to the data published by Springer Nature, according to that in the last decades, optimizations of isolation, culture, and differentiation procedures have permitted mesenchymal stem cells (MSCs) to improve closer to clinical uses for improving disorders and various tissue regeneration. According to the studies described in this literature, the administration of mesenchymal stem cells (MSCs) appears to be more effective and the usefulness of MSC therapy in bone and heart disorders has been broadly established
- Among stem cell type, anterior pluripotent stem cells (iPSC/ESCs) is expected to dominate the global stem cell cartilage regeneration market over the forecast period, due to the increase in the number of successful treatments.
- Major players operating in the global stem cell cartilage regeneration market include Theracell Advanced Biotechnology Ltd., Orthocell Ltd., Xintela AB, CellGenix GmbH, Merck KGaA, Osiris Therapeutics, Inc., BioTissue SA, and Vericel Corporation, and other prominent players
